haematology
Age-Adjusted IPI (aa-IPI) for Aggressive Lymphoma
Simplified prognostic index for patients ≤60 years with aggressive non-Hodgkin lymphoma (Shipp 1993). Three factors: stage, LDH, performance status.
Score interpretation
Low risk (5-y OS ~83%) 0
→ Standard R-CHOP × 6.
Low-intermediate risk (~69%) 1
→ R-CHOP × 6 with attention to dose intensity and PET response.
High-intermediate risk (~46%) 2
→ Consider intensified therapy or trial enrolment; CNS-IPI assessment.
High risk (~32%) 3
→ Trial enrolment / intensified regimens; CNS prophylaxis indicated; close interim assessment for early salvage.
Interpretation bands for the aa-IPI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- Ann Arbor Staging for Lymphoma · Lymphoma
- CNS International Prognostic Index (CNS-IPI) for DLBCL · Lymphoma
- NCCN-IPI for Diffuse Large B-Cell Lymphoma · Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) · Lymphoma
- Mantle Cell Lymphoma International Prognostic Index (MIPI) · Lymphoma
Drugs
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.